Brought to you by 
Innovex to sell Scios's Natrecor
19 Aug 2002
Executive Summary
CRO Quintiles' marketing arm Innovex will sell in the US and Puerto Rico Scios's lead drug Natrecor (nesiritide), which is awaiting FDA approval for treating congestive heart failure. Innovex will create a sales force of 180 which Scios has an option to acquire.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innovex to sell Scios's Natrecor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice